Skip to main content

Table 1 Treatment effects applied in the analysis

From: Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

 

HbA1c change from baseline (%)

BMI change from baseline (%)

Non-severe hypoglycaemia

(events per 100 patient-year)

Source

IDegLira

-1.66

0.04

24.00

DUAL I China

liraglutide

-1.04

-0.86

4

DUAL I China

degludec

-1.13

0.43

17

DUAL I China